Liposomal anthracycline chemotherapy

This page covers all Liposomal anthracycline chemotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Topoisomerase II, DNA (topoisomerase II inhibitor).

Targets

Topoisomerase II · DNA (topoisomerase II inhibitor)

Marketed (1)

• DSP · Taiwan Liposome Company · Oncology
  DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity.

Phase 3 pipeline (1)

• DaunoXome · Gruppo Italiano Malattie EMatologiche dell'Adulto · Oncology
  DaunoXome is a liposomal formulation of daunorubicin that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cells.